Clinical trials: Cardiac Perfusion
- Condition Cardiac Perfusion
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Coronary Artery Disease
A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET
Safety and dosimetry of BFPET™ will be evaluated in healthy volunteers and Coronary Artery Disease (CAD) patients , male or female and of age ranging between 20-80 years old.
- Trial name
- NCT00733460
- Testing
- BFPET
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Fluoropharma, Inc.
Coronary Artery Disease (CAD), Myocardial Ischemia
A Study of XTR004 Radiotracer in Healthy Volunteers
XTR004 is a 18F-labeled myocardial perfusion positron emission tomography tracer use to measure myocardial perfusion and myocardial blood flow.
- Trial name
- NCT05195879
- Testing
- XTR004
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Fontan, Right Heart Failure
Cholate Clearance in Fontan and Heart Failure
The goal of this study is to use the HepQuant dual cholate clearance assay, which has been shown to measure liver function in people with known chronic liver conditions, to assess severity of Fontan-associated liver disease…
- Trial name
- NCT07009132
- Testing
- Dual cholate clearance assay, MRI
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- HepQuant, LLC
Coronary Artery Disease
A Phase I Study of a Novel Tracer for Positron Emission Tomography "PET" Myocardial Perfusion Imaging "MPI"
[11C]-dimethyl-diphenyl ammonium ([11C]-DMDPA) - A Phase I, Open-label, Safety and Tolerability, Radiation Dosimetry, Biodistribution, First-in-Human Study of a Novel 11C-labeled Tracer for Positron Emission Tomography Myocardial…
- Trial name
- NCT02720354
- Testing
- [11C]-DMDPA
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Synektik S.A.
Heart Failure With Reduced Ejection Fraction (HFrEF), Renal Impairment
AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment
The present study is designed to test the effect of AZD3427 on renal perfusion in participants with heart failure and reduced eGFR (30 to 90 mL/min/1.73m2).
- Trial name
- Re-PERFUSE (NCT06611423)
- Testing
- AZD3427, Dopamine, Radiolabelled ligand
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Artery Disease
Acquiring Consensus for Contrast Echocardiography System Settings - ACCESS Study
This study evaluated and optimized settings for, and evaluated the performance of, AI-700-enhanced echocardiographic imaging on several ultrasound imaging platforms, as well as collected additional safety data for AI-700 in…
- Trial name
- NCT00669851
- Testing
- AI-700
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Acusphere
Coronary Artery Disease, Healthy
Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems
The purpose of this clinical trial is to evaluate various commercially available ultrasound systems and to identify imaging parameters to be used with these systems (along with the contrast agent PB127) as well as to further…
- Trial name
- NCT00487903
- Testing
- PB127 for Injectable Suspension
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Point Biomedical
Healthy, Coronary Artery Disease
Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease
The purpose of this study is to determine the dose of PB127 for detection and/or exclusion of coronary artery disease when used with cardiac ultrasound. This study also evaluates the safety of PB127.
- Trial name
- NCT00584818
- Testing
- PB127 for Injectable Suspension
- Where
- 16 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Point Biomedical